PNC Financial Services Group Inc. Acquires 3,593 Shares of Omnicell, Inc. (NASDAQ:OMCL)

PNC Financial Services Group Inc. lifted its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 51.6% in the 4th quarter, HoldingsChannel.com reports. The fund owned 10,551 shares of the company’s stock after buying an additional 3,593 shares during the period. PNC Financial Services Group Inc.’s holdings in Omnicell were worth $470,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Smartleaf Asset Management LLC raised its position in shares of Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock worth $35,000 after acquiring an additional 273 shares in the last quarter. Van ECK Associates Corp raised its position in shares of Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after acquiring an additional 315 shares in the last quarter. First Horizon Advisors Inc. raised its position in shares of Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after acquiring an additional 355 shares in the last quarter. KBC Group NV raised its position in shares of Omnicell by 60.8% in the 4th quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after acquiring an additional 778 shares in the last quarter. Finally, CIBC Asset Management Inc bought a new position in shares of Omnicell in the 4th quarter worth about $201,000. 97.70% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

OMCL has been the subject of several research analyst reports. Benchmark reissued a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a research report on Tuesday, February 4th. StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a research note on Thursday, March 6th. JPMorgan Chase & Co. raised their target price on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Bank of America reduced their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research note on Monday, January 6th. Finally, Wells Fargo & Company reduced their target price on Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Omnicell presently has a consensus rating of “Hold” and a consensus target price of $52.33.

Omnicell Price Performance

OMCL stock opened at $34.70 on Thursday. The company has a market capitalization of $1.62 billion, a P/E ratio of 128.52, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.75. The business has a 50-day simple moving average of $40.10 and a two-hundred day simple moving average of $43.04.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Research analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.